<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00354601</url>
  </required_header>
  <id_info>
    <org_study_id>CCCWFU-83203</org_study_id>
    <secondary_id>CCCWFU-83203</secondary_id>
    <secondary_id>CCCWFU-BG05-536</secondary_id>
    <secondary_id>AVENTIS-CCCWFU-83203</secondary_id>
    <secondary_id>CDR0000489036</secondary_id>
    <secondary_id>ROCHE-CCCWFU-BG05-536</secondary_id>
    <nct_id>NCT00354601</nct_id>
  </id_info>
  <brief_title>Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer</brief_title>
  <official_title>A Phase II Study of Weekly Docetaxel and Capecitabine for Persistent or Recurrent Platinum Resistant Epithelial Carcinoma of the Ovary, Fallopian Tube or Peritoneum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel and capecitabine, work in different
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
      dividing. Giving docetaxel together with carboplatin may kill more tumor cells.

      PURPOSE: This phase II trial is studying how well giving docetaxel together with capecitabine
      works in treating patients with recurrent or persistent ovarian epithelial cancer, fallopian
      tube cancer, or peritoneal cavity cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the response rate in patients with recurrent or persistent ovarian epithelial
           cancer, fallopian tube cancer, or peritoneal cavity cancer treated with docetaxel and
           capecitabine.

      Secondary

        -  Determine the time to progression in patients treated with this regimen.

        -  Determine the toxicity of this regimen in these patients.

        -  Determine the quality of life during treatment of these patients.

      OUTLINE: Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral
      capecitabine twice daily on days 1-21. Treatment repeats every 28 days for ≥ 6 courses in the
      absence of disease progression or unacceptable toxicity.

      Quality of life is assessed at baseline, on day 1 of each course, and then at completion of
      study treatment.

      After completion of study treatment, patients are followed every 2-3 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    funding withdrawn
  </why_stopped>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Tumor Response</measure>
    <time_frame>8 weeks</time_frame>
    <description>The number of partial and complete responders among all evaluable patients as defined using Response Evaluation Criteria in Solid Tumors guidelines</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>Evaluated every 8 weeks during treatment</time_frame>
    <description>Progression is defined as a 20% increase in tumor size of all the target lesions along the longest diameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Grade 3 or Higher Toxicity</measure>
    <time_frame>Days 1, 8, 15, 21 of each course and treatment end (28 days after last dose or start of new therapy)</time_frame>
    <description>summary of grade 3 (per Common Toxicity Criteria) or higher toxicities which generally is described as a severe adverse reaction or symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Pre-entry, day 1, treatment end</time_frame>
    <description>comparison of treatment end to pre entry and day 1 of each treatment cycle.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Peritoneal Cavity Cancer</condition>
  <arm_group>
    <arm_group_label>Weekly Docetaxel and Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly Docetaxel and Capecitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>oral capecitabine twice daily on days 1-21</description>
    <arm_group_label>Weekly Docetaxel and Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>docetaxel IV over 30 minutes on days 1, 8, and 15</description>
    <arm_group_label>Weekly Docetaxel and Capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of 1 of the following:

               -  Ovarian epithelial adenocarcinoma

               -  Fallopian tube cancer

               -  Peritoneal cavity cancer

          -  Recurrent or persistent disease after no more than 2 prior treatment regimens (1
             regimen for primary disease and/or 1 regimen for recurrent disease)

          -  Platinum-resistant disease, defined as 1 of the following:

               -  Treatment-free interval &lt; 6 months after platinum-based therapy

               -  Disease progression during platinum-based therapy

          -  Measurable disease by physical exam, chest x-ray, CT scan, or MRI

          -  No brain metastases

        PATIENT CHARACTERISTICS:

          -  Gynecologic Oncology Group performance status 0-2

          -  Life expectancy &gt; 6 months

          -  Absolute neutrophil count ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 8 g/dL

          -  Creatinine clearance ≥ 50 mL/min

          -  Bilirubin normal

          -  AST or ALT and alkaline phosphatase (AP) meeting 1 of the following criteria:

               -  AST or ALT ≤ 5 times upper limit of normal (ULN) AND AP normal

               -  AST or ALT ≤ 1.5 times ULN AND AP ≤ 2.5 times ULN

               -  AST or ALT normal AND AP ≤ 5 times ULN

          -  No peripheral neuropathy &gt; grade 2

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 6 months after
             completion of study treatment

          -  No other concurrent malignancy except for curatively treated nonmelanoma skin cancer

          -  No prior invasive malignancy &lt; 5 years after curative therapy

          -  No serious uncontrolled medical or psychiatric illness that would preclude study
             participation or limit survival to &lt; 6 months

          -  No history of severe hypersensitivity reaction to drugs formulated with polysorbate 80
             or to fluoropyrimidine therapy or fluorouracil

          -  No inability to tolerate oral medication due to bowel obstruction, lack of physical
             integrity of the upper gastrointestinal tract, inability to swallow, or malabsorption
             syndrome

          -  No serious concurrent infections

          -  No clinically significant cardiac disease not well controlled with medication,
             including any of the following:

               -  Congestive heart failure

               -  Symptomatic coronary artery disease

               -  Symptomatic cardiac arrhythmias

               -  Myocardial infarction within the past 12 months

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior docetaxel or capecitabine or other fluoropyrimidine therapy

          -  Recovered from prior therapy

          -  At least 2 weeks since prior major surgery

          -  At least 4 weeks since prior chemotherapy, hormone therapy, or radiotherapy

          -  No other concurrent chemotherapeutic agents, biological therapy, radiotherapy, or
             other investigational agents
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigitte E. Miller, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2006</study_first_submitted>
  <study_first_submitted_qc>July 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2006</study_first_posted>
  <results_first_submitted>March 9, 2009</results_first_submitted>
  <results_first_submitted_qc>May 15, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 18, 2009</results_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fallopian tube cancer</keyword>
  <keyword>peritoneal cavity cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>ovarian clear cell cystadenocarcinoma</keyword>
  <keyword>ovarian endometrioid adenocarcinoma</keyword>
  <keyword>ovarian mucinous cystadenocarcinoma</keyword>
  <keyword>ovarian serous cystadenocarcinoma</keyword>
  <keyword>ovarian undifferentiated adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients enrolled 01/23/2006 to 03/16/2007 at which time the protocol was suspended for lack of funding</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Docetaxel and Capecitabine</title>
          <description>Docetaxel and Capecitabine therapy per protocol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Docetaxel and Capecitabine</title>
          <description>Docetaxel and Capecitabine therapy per protocol</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.15" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>Progression is defined as a 20% increase in tumor size of all the target lesions along the longest diameter</description>
        <time_frame>Evaluated every 8 weeks during treatment</time_frame>
        <population>unable to analyze due to failure to complete treatment or study</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel and Capecitabine</title>
            <description>Docetaxel and Capecitabine therapy per protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>Progression is defined as a 20% increase in tumor size of all the target lesions along the longest diameter</description>
          <population>unable to analyze due to failure to complete treatment or study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Grade 3 or Higher Toxicity</title>
        <description>summary of grade 3 (per Common Toxicity Criteria) or higher toxicities which generally is described as a severe adverse reaction or symptom.</description>
        <time_frame>Days 1, 8, 15, 21 of each course and treatment end (28 days after last dose or start of new therapy)</time_frame>
        <population>tracked during incomplete treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel and Capecitabine</title>
            <description>Docetaxel and Capecitabine therapy per protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 3 or Higher Toxicity</title>
          <description>summary of grade 3 (per Common Toxicity Criteria) or higher toxicities which generally is described as a severe adverse reaction or symptom.</description>
          <population>tracked during incomplete treatment period</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <description>comparison of treatment end to pre entry and day 1 of each treatment cycle.</description>
        <time_frame>Pre-entry, day 1, treatment end</time_frame>
        <population>neither patient completed study</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel and Capecitabine</title>
            <description>Docetaxel and Capecitabine therapy per protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life</title>
          <description>comparison of treatment end to pre entry and day 1 of each treatment cycle.</description>
          <population>neither patient completed study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective Tumor Response</title>
        <description>The number of partial and complete responders among all evaluable patients as defined using Response Evaluation Criteria in Solid Tumors guidelines</description>
        <time_frame>8 weeks</time_frame>
        <population>unable to measure due to failure to complete</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel and Capecitabine</title>
            <description>Docetaxel and Capecitabine therapy per protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Tumor Response</title>
          <description>The number of partial and complete responders among all evaluable patients as defined using Response Evaluation Criteria in Solid Tumors guidelines</description>
          <population>unable to measure due to failure to complete</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Docetaxel and Capecitabine</title>
          <description>Docetaxel and Capecitabine therapy per protocol</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC version 3</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash: hand-foot skin reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTC version 3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Taste alteration (dysgeusia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early closure due to discontinuation of funding</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Doug Case Biostatistician</name_or_title>
      <organization>Wake Forest University Health Sciences</organization>
      <phone>336-716-1048</phone>
      <email>dcase@wfubmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

